{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:13:38Z","timestamp":1792174418588,"version":"4.4.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS133688"],"award-info":[{"award-number":["R01NS133688"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["P01CA203653"],"award-info":[{"award-number":["P01CA203653"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["R01AG071512"],"award-info":[{"award-number":["R01AG071512"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["HT94252310443"],"award-info":[{"award-number":["HT94252310443"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008136","name":"Case Western Reserve University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008136","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.neurot.2025.e00586","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T16:09:31Z","timestamp":1744128571000},"page":"e00586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Nrf2\/Bach1 signaling axis: A promising multifaceted therapeutic strategy for Alzheimer's disease"],"prefix":"10.1016","volume":"22","author":[{"given":"Priyanka","family":"Soni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarshana M.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Pieper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindu D.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobby","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.neurot.2025.e00586_bib1","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1002\/alz.13809","article-title":"2024 Alzheimer's disease facts and figures","volume":"20","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurot.2025.e00586_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.937486","article-title":"Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2019","volume":"14","author":"Li","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.neurot.2025.e00586_bib3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.redox.2017.10.014","article-title":"Oxidative stress and the amyloid beta peptide in Alzheimer's disease","volume":"14","author":"Cheignon","year":"2018","journal-title":"Redox Biol"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00586_bib4","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-beta pathway in alzheimer's disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol Psychiatr"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00586_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10753-022-01721-1","article-title":"Neuroinflammation in alzheimer's disease: current progress in molecular signaling and therapeutics","volume":"46","author":"Thakur","year":"2023","journal-title":"Inflammation"},{"key":"10.1016\/j.neurot.2025.e00586_bib6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.freeradbiomed.2018.09.033","article-title":"Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration","volume":"133","author":"Masaldan","year":"2019","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00586_bib7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00204-023-03660-8","article-title":"Ferroptosis regulation through Nrf2 and implications for neurodegenerative diseases","volume":"98","author":"Xiang","year":"2024","journal-title":"Arch Toxicol"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00586_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24081583","article-title":"Oxidative stress: a key modulator in neurodegenerative diseases","volume":"24","author":"Singh","year":"2019","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00586_bib9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3233\/JAD-190863","article-title":"Molecular mechanisms and genetics of oxidative stress in Alzheimer's disease","volume":"72","author":"Cioffi","year":"2019","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00586_bib10","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00204-015-1556-z","article-title":"Oxidative stress in Alzheimer disease and mild cognitive impairment: evidence from human data provided by redox proteomics","volume":"89","author":"Swomley","year":"2015","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.neurot.2025.e00586_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/1759091419899782","article-title":"NRF2 as a therapeutic target in neurodegenerative diseases","volume":"12","author":"Brandes","year":"2020","journal-title":"ASN Neuro"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00586_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tips.2022.12.003","article-title":"Advances and challenges in therapeutic targeting of NRF2","volume":"44","author":"Dinkova-Kostova","year":"2023","journal-title":"Trends Pharmacol Sci"},{"issue":"31","key":"10.1016\/j.neurot.2025.e00586_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo5633","article-title":"Identification of the NRF2 transcriptional network as a therapeutic target for trigeminal neuropathic pain","volume":"8","author":"Vasavda","year":"2022","journal-title":"Sci Adv"},{"issue":"13","key":"10.1016\/j.neurot.2025.e00586_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00099-20","article-title":"The molecular mechanisms regulating the KEAP1-NRF2 pathway","volume":"40","author":"Baird","year":"2020","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.neurot.2025.e00586_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.673205","article-title":"Challenges and limitations of targeting the Keap1-Nrf2 pathway for neurotherapeutics: Bach1 De-repression to the Rescue","volume":"13","author":"Hushpulian","year":"2021","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00586_bib16","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3233\/JAD-161032","article-title":"Meta-analysis of Parkinson's disease and Alzheimer's disease revealed commonly impaired pathways and dysregulation of NRF2-dependent genes","volume":"56","author":"Wang","year":"2017","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00586_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/biom13030549","article-title":"The role of the transcription factor Nrf2 in Alzheimer's disease: therapeutic opportunities","volume":"13","author":"De Plano","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.neurot.2025.e00586_bib18","article-title":"A\u00a0perspective on Nrf2 signaling pathway for neuroinflammation: a potential therapeutic target in Alzheimer's and Parkinson's diseases","volume":"15","author":"Saha","year":"2021","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.neurot.2025.e00586_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101756","article-title":"Role of Nrf2 in aging, Alzheimer's and other neurodegenerative diseases","volume":"82","author":"George","year":"2022","journal-title":"Ageing Res Rev"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00586_bib20","doi-asserted-by":"crossref","first-page":"7517","DOI":"10.1007\/s12035-024-04023-9","article-title":"NRF2 deficiency promotes ferroptosis of astrocytes mediated by oxidative stress in Alzheimer's disease","volume":"61","author":"Tang","year":"2024","journal-title":"Mol Neurobiol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00586_bib21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/nen.0b013e31802d6da9","article-title":"Expression of Nrf2 in neurodegenerative diseases","volume":"66","author":"Ramsey","year":"2007","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"issue":"25","key":"10.1016\/j.neurot.2025.e00586_bib22","doi-asserted-by":"crossref","first-page":"12516","DOI":"10.1073\/pnas.1819541116","article-title":"NRF2\/ARE pathway negatively regulates BACE1 expression and ameliorates cognitive deficits in mouse Alzheimer's models","volume":"116","author":"Bahn","year":"2019","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.neurot.2025.e00586_bib23","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.redox.2017.07.006","article-title":"NRF2 deficiency replicates transcriptomic changes in Alzheimer's patients and worsens APP and TAU pathology","volume":"13","author":"Rojo","year":"2017","journal-title":"Redox Biol"},{"key":"10.1016\/j.neurot.2025.e00586_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1437939","article-title":"Targeting the NRF2 pathway for disease modification in neurodegenerative diseases: mechanisms and therapeutic implications","volume":"15","author":"Mayer","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.neurot.2025.e00586_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101107","article-title":"NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis","volume":"23","author":"Dodson","year":"2019","journal-title":"Redox Biol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00586_bib26","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/glia.23741","article-title":"NF-E2-related factor 2 activation boosts antioxidant defenses and ameliorates inflammatory and amyloid properties in human Presenilin-1 mutated Alzheimer's disease astrocytes","volume":"68","author":"Oksanen","year":"2020","journal-title":"Glia"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00586_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00467-19","article-title":"Nrf2 suppresses oxidative stress and inflammation in App Knock-in Alzheimer's disease model mice","volume":"40","author":"Uruno","year":"2020","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00586_bib28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11011-023-01278-4","article-title":"Triptolide activates the Nrf2 signaling pathway and inhibits the NF-kappaB signaling pathway to improve Alzheimer disease","volume":"39","author":"He","year":"2024","journal-title":"Metab Brain Dis"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00586_bib29","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/1567205012666150921101430","article-title":"Reductive stress: a new concept in Alzheimer's disease","volume":"13","author":"Lloret","year":"2016","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.neurot.2025.e00586_bib30","article-title":"Reductive stress promotes protein aggregation and impairs neurogenesis","volume":"37","author":"Kk","year":"2020","journal-title":"Redox Biol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00586_bib31","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cmet.2023.01.012","article-title":"NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer","volume":"35","author":"Weiss-Sadan","year":"2023","journal-title":"Cell Metab"},{"issue":"25","key":"10.1016\/j.neurot.2025.e00586_bib32","first-page":"00031","article-title":"Reductive stress: The key pathway in metabolic disorders induced by overnutrition","volume":"S2090-1232","author":"Zhang","year":"2025","journal-title":"J\u00a0Adv Res"},{"key":"10.1016\/j.neurot.2025.e00586_bib33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.freeradbiomed.2024.02.021","article-title":"Redox-associated changes in healthy individuals at risk of Alzheimer's disease. A ten-year follow-up study","volume":"215","author":"Nepomuceno","year":"2024","journal-title":"Free Radic Biol Med"},{"issue":"5440","key":"10.1016\/j.neurot.2025.e00586_bib34","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.286.5440.735","article-title":"Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE","volume":"286","author":"Vassar","year":"1999","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00586_bib35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/85064","article-title":"BACE1 is the major beta-secretase for generation of Abeta peptides by neurons","volume":"4","author":"Cai","year":"2001","journal-title":"Nat Neurosci"},{"issue":"6101","key":"10.1016\/j.neurot.2025.e00586_bib36","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1126\/science.1228541","article-title":"Preventing Alzheimer's disease","volume":"337","author":"Selkoe","year":"2012","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00586_bib37","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.biopsych.2020.02.001","article-title":"The beta-Secretase BACE1 in Alzheimer's Disease","volume":"89","author":"Hampel","year":"2021","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.neurot.2025.e00586_bib38","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1038\/ncomms4496","article-title":"Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52","volume":"5","author":"Jo","year":"2014","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00586_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ph15060692","article-title":"A\u00a0pivotal role of Nrf2 in neurodegenerative disorders: a new way for therapeutic strategies","volume":"15","author":"Suzen","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00586_bib40","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1007\/s11010-023-04878-x","article-title":"NRF2 signaling pathway and telomere length in aging and age-related diseases","volume":"479","author":"Medoro","year":"2024","journal-title":"Mol Cell Biochem"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00586_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10082043","article-title":"The role of the NRF2 pathway in maintaining and improving cognitive function","volume":"10","author":"Gray","year":"2022","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00586_bib42","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.4103\/1673-5374.194706","article-title":"The status of Nrf2-based therapeutics: current perspectives and future prospects","volume":"11","author":"Gazaryan","year":"2016","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.neurot.2025.e00586_bib43","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.redox.2017.01.006","article-title":"Modulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseases","volume":"11","author":"Pajares","year":"2017","journal-title":"Redox Biol"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00586_bib44","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1111\/j.1471-4159.2006.03995.x","article-title":"Pin1 in Alzheimer's disease","volume":"98","author":"Butterfield","year":"2006","journal-title":"J\u00a0Neurochem"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00586_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cells10040721","article-title":"GSK-3 and tau: a key Duet in Alzheimer's disease","volume":"10","author":"Sayas","year":"2021","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00586_bib46","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1134\/S0006297921040052","article-title":"A\u00a0crosstalk between the biorhythms and gatekeepers of longevity: dual role of glycogen synthase kinase-3","volume":"86","author":"Shilovsky","year":"2021","journal-title":"Biochemistry (Mosc)."},{"issue":"Pt 1","key":"10.1016\/j.neurot.2025.e00586_bib47","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/brain\/awt323","article-title":"Fractalkine activates NRF2\/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis","volume":"137","author":"Lastres-Becker","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00586_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2024.102511","article-title":"Neuroprotective signaling by hydrogen sulfide and its dysregulation in Alzheimer's disease","volume":"82","author":"Paul","year":"2024","journal-title":"Curr Opin Chem Biol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00586_bib49","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3233\/JAD-2011-110092","article-title":"Oxidative and nitrosative modifications of biliverdin reductase-A in the brain of subjects with Alzheimer's disease and amnestic mild cognitive impairment","volume":"25","author":"Barone","year":"2011","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"20","key":"10.1016\/j.neurot.2025.e00586_bib50","doi-asserted-by":"crossref","first-page":"7109","DOI":"10.1073\/pnas.0502173102","article-title":"Human biliverdin reductase: a member of the insulin receptor substrate family with serine\/threonine\/tyrosine kinase activity","volume":"102","author":"Lerner-Marmarosh","year":"2005","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"11","key":"10.1016\/j.neurot.2025.e00586_bib51","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.tibs.2024.09.004","article-title":"Bridging brain insulin resistance to Alzheimer's pathogenesis","volume":"49","author":"Chen","year":"2024","journal-title":"Trends Biochem Sci"},{"issue":"48","key":"10.1016\/j.neurot.2025.e00586_bib52","doi-asserted-by":"crossref","first-page":"25179","DOI":"10.1074\/jbc.M116.731703","article-title":"Biliverdin reductase A attenuates hepatic steatosis by inhibition of glycogen synthase kinase (GSK) 3beta phosphorylation of serine 73 of peroxisome proliferator-activated receptor (PPAR) alpha","volume":"291","author":"Hinds","year":"2016","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.neurot.2025.e00586_bib53","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.nbd.2019.02.003","article-title":"Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer's disease","volume":"125","author":"Sharma","year":"2019","journal-title":"Neurobiol Dis"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00586_bib54","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13195-022-00996-8","article-title":"Glucose metabolism and AD: evidence for a potential diabetes type 3","volume":"14","author":"Gonzalez","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00586_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12987-018-0121-6","article-title":"Disruption of the hippocampal and hypothalamic blood-brain barrier in a diet-induced obese model of type II diabetes: prevention and treatment by the mitochondrial carbonic anhydrase inhibitor, topiramate","volume":"16","author":"Salameh","year":"2019","journal-title":"Fluids Barriers CNS"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00586_bib56","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1093\/cercor\/bht101","article-title":"Altered expression of diabetes-related genes in Alzheimer's disease brains: the Hisayama study","volume":"24","author":"Hokama","year":"2014","journal-title":"Cerebr Cortex"},{"key":"10.1016\/j.neurot.2025.e00586_bib57","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.redox.2017.08.014","article-title":"Aging-related decline in the induction of Nrf2-regulated antioxidant genes in human bronchial epithelial cells","volume":"14","author":"Zhou","year":"2018","journal-title":"Redox Biol"},{"key":"10.1016\/j.neurot.2025.e00586_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2019.108074","article-title":"Silencing Bach1 alters aging-related changes in the expression of Nrf2-regulated genes in primary human bronchial epithelial cells","volume":"672","author":"Zhang","year":"2019","journal-title":"Arch Biochem Biophys"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00586_bib59","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3233\/JAD-141254","article-title":"Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1\/BVR-a system: insights for transition to Alzheimer's disease","volume":"44","author":"Di Domenico","year":"2015","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00586_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/antiox9090779","article-title":"The BACH1\/Nrf2 Axis in brain in down syndrome and transition to Alzheimer disease-like Neuropathology and dementia","volume":"9","author":"Perluigi","year":"2020","journal-title":"Antioxidants"},{"issue":"67","key":"10.1016\/j.neurot.2025.e00586_bib61","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-7091-6721-2_3","article-title":"Aberrant protein expression of transcription factors BACH1 and ERG, both encoded on chromosome 21, in brains of patients with Down syndrome and Alzheimer's disease","author":"Shim","year":"2003","journal-title":"J\u00a0Neural Transm Suppl"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00586_bib62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1756285614564152","article-title":"Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview","volume":"8","author":"Bomprezzi","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"issue":"23","key":"10.1016\/j.neurot.2025.e00586_bib63","doi-asserted-by":"crossref","first-page":"6332","DOI":"10.1523\/JNEUROSCI.0426-16.2016","article-title":"Distinct Nrf2 signaling mechanisms of fumaric acid Esters and their role in neuroprotection against 1-methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-induced Experimental Parkinson's-like disease","volume":"36","author":"Ahuja","year":"2016","journal-title":"J\u00a0Neurosci"},{"issue":"45","key":"10.1016\/j.neurot.2025.e00586_bib64","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111643118","article-title":"Bach1 derepression is neuroprotective in a mouse model of Parkinson's disease","volume":"118","author":"Ahuja","year":"2021","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"10.1016\/j.neurot.2025.e00586_bib65","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0022-3999(87)90072-9","article-title":"Eating style: a validation study of the Dutch Eating Behaviour Questionnaire in normal subjects and women with eating disorders","volume":"31","author":"Wardle","year":"1987","journal-title":"J\u00a0Psychosom Res"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00586_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/antiox11091780","article-title":"Harnessing the therapeutic potential of the Nrf2\/Bach1 signaling pathway in Parkinson's disease","volume":"11","author":"Ahuja","year":"2022","journal-title":"Antioxidants"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00586_bib67","first-page":"211","article-title":"Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis","volume":"3","author":"Hansen","year":"2008","journal-title":"Clin Interv Aging"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00586_bib68","article-title":"Donepezil for dementia due to Alzheimer's disease","volume":"6","author":"Birks","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurot.2025.e00586_bib69","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2147\/CIA.S290055","article-title":"The efficacy of Transdermal rivastigmine in mild to moderate Alzheimer's disease with Concomitant small Vessel Cerebrovascular disease: findings from an Open-Label study","volume":"16","author":"Yatawara","year":"2021","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.neurot.2025.e00586_bib70","first-page":"35","article-title":"Pharmacological aspects of galantamine for the treatment of Alzheimer's disease","volume":"16","author":"Kim","year":"2017","journal-title":"EXCLI J"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00586_bib71","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","article-title":"Anti-amyloid monoclonal antibodies for the treatment of Alzheimer's disease","volume":"38","author":"Cummings","year":"2024","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00586_bib72","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00586_bib73","doi-asserted-by":"crossref","DOI":"10.52965\/001c.31925","article-title":"Aducanumab, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer's disease: a comprehensive review","volume":"10","author":"Haddad","year":"2022","journal-title":"Health Psychol Res"},{"issue":"20","key":"10.1016\/j.neurot.2025.e00586_bib74","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of Gantenerumab in early Alzheimer's disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.neurot.2025.e00586_bib75","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00586_bib76","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/13543784.2023.2178414","article-title":"Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease","volume":"32","author":"Vitek","year":"2023","journal-title":"Expet Opin Invest Drugs"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00586_bib77","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s40001-023-01512-w","article-title":"The FDA-approved anti-amyloid-beta monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Wu","year":"2023","journal-title":"Eur J Med Res"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00586_bib78","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s40265-021-01569-z","article-title":"Aducanumab: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.neurot.2025.e00586_bib79","article-title":"Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development","volume":"20","author":"Brockmann","year":"2023","journal-title":"Lancet Reg Health Am"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00586_bib80","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Safety and efficacy of Semorinemab in individuals with prodromal to mild Alzheimer disease: a randomized clinical trial","volume":"79","author":"Teng","year":"2022","journal-title":"JAMA Neurol"},{"issue":"14","key":"10.1016\/j.neurot.2025.e00586_bib81","doi-asserted-by":"crossref","first-page":"e1391","DOI":"10.1212\/WNL.0000000000207663","article-title":"Randomized phase II study of the safety and efficacy of Semorinemab in participants with mild-to-moderate Alzheimer disease: lauriet","volume":"101","author":"Monteiro","year":"2023","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00586_bib82","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208061","article-title":"Assessment of efficacy and safety of Zagotenemab: results from PERISCOPE-ALZ, a phase 2 study in early symptomatic Alzheimer disease","volume":"102","author":"Fleisher","year":"2024","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00586_bib83","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/brain\/awad024","article-title":"Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study","volume":"146","author":"Florian","year":"2023","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00586_bib84","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for Alzheimer disease: current status and future directions","volume":"19","author":"Congdon","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurot.2025.e00586_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1391517","article-title":"The emerging role of brain neuroinflammatory responses in Alzheimer's disease","volume":"16","author":"Amelimojarad","year":"2024","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00586_bib86","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12974-024-03163-y","article-title":"Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?","volume":"21","author":"Lista","year":"2024","journal-title":"J\u00a0Neuroinflammation"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00586_bib87","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.biopsych.2017.10.023","article-title":"(-)-P7C3-S243 protects a rat model of Alzheimer's disease from neuropsychiatric deficits and neurodegeneration without altering amyloid deposition or reactive Glia","volume":"84","author":"Voorhees","year":"2018","journal-title":"Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00586_bib88","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2017225118","article-title":"Hydrogen sulfide is neuroprotective in Alzheimer's disease by sulfhydrating GSK3beta and inhibiting Tau hyperphosphorylation","volume":"118","author":"Giovinazzo","year":"2021","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.neurot.2025.e00586_bib89","doi-asserted-by":"crossref","DOI":"10.1111\/bph.16170","article-title":"Hydrogen sulfide signalling in neurodegenerative diseases","author":"Tripathi","year":"2023","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00586_bib90","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/jnc.15332","article-title":"Regulators of cholinergic signaling in disorders of the central nervous system","volume":"158","author":"Winek","year":"2021","journal-title":"J\u00a0Neurochem"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00586_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27061816","article-title":"Role of cholinergic signaling in Alzheimer's disease","volume":"27","author":"Chen","year":"2022","journal-title":"Molecules"},{"issue":"20","key":"10.1016\/j.neurot.2025.e00586_bib92","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21207452","article-title":"The dual role of glutamatergic neurotransmission in Alzheimer's disease: from pathophysiology to pharmacotherapy","volume":"21","author":"Bukke","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurot.2025.e00586_bib93","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.nbd.2017.02.010","article-title":"Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice","volume":"102","author":"MacPherson","year":"2017","journal-title":"Neurobiol Dis"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00586_bib94","doi-asserted-by":"crossref","first-page":"149","DOI":"10.14283\/jpad.2018.18","article-title":"Development of Azeliragon, an oral small molecule antagonist of the receptor for advanced Glycation Endproducts, for the potential slowing of loss of cognition in mild Alzheimer's disease","volume":"5","author":"Burstein","year":"2018","journal-title":"J\u00a0Prev Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00586_bib95","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40263-019-00613-7","article-title":"A\u00a0Close Look at BACE1 inhibitors for Alzheimer's disease treatment","volume":"33","author":"Das","year":"2019","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00586_bib96","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","article-title":"Efficacy and safety of Lanabecestat for treatment of early and mild Alzheimer disease: the AMARANTH and DAYBREAK-ALZ randomized clinical trials","volume":"77","author":"Wessels","year":"2020","journal-title":"JAMA Neurol"},{"issue":"15","key":"10.1016\/j.neurot.2025.e00586_bib97","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of Verubecestat for prodromal Alzheimer's disease","volume":"380","author":"Egan","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00586_bib98","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00586_bib99","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","article-title":"Evaluating the safety and efficacy of Crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized Placebo-controlled trials","volume":"79","author":"Ostrowitzki","year":"2022","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00586_bib100","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00586_bib101","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2214\/AJR.22.28461","article-title":"Amyloid-related imaging abnormalities: an update","volume":"220","author":"Roytman","year":"2023","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00586_bib102","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/d41573-020-00217-7","article-title":"Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00586_bib103","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/1673-5374.340409","article-title":"Initial failures of anti-tau antibodies in Alzheimer's disease are reminiscent of the amyloid-beta story","volume":"18","author":"Imbimbo","year":"2023","journal-title":"Neural Regen Res"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00586_bib104","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1152\/physrev.00030.2022","article-title":"Oxidative damage in neurodegeneration: roles in the pathogenesis and progression of Alzheimer disease","volume":"104","author":"Perluigi","year":"2024","journal-title":"Physiol Rev"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00586_bib105","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00204-023-03476-6","article-title":"ROS-induced lipid peroxidation modulates cell death outcome: mechanisms behind apoptosis, autophagy, and ferroptosis","volume":"97","author":"Wang","year":"2023","journal-title":"Arch Toxicol"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00586_bib106","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0891-5849(02)00794-3","article-title":"Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress","volume":"32","author":"Butterfield","year":"2002","journal-title":"Free Radic Biol Med"},{"issue":"7000","key":"10.1016\/j.neurot.2025.e00586_bib107","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nature02621","article-title":"Pathways towards and away from Alzheimer's disease","volume":"430","author":"Mattson","year":"2004","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00586_bib108","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13024-025-00803-6","article-title":"Lipidome disruption in Alzheimer's disease brain: detection, pathological mechanisms, and therapeutic implications","volume":"20","author":"He","year":"2025","journal-title":"Mol Neurodegener"},{"issue":"34","key":"10.1016\/j.neurot.2025.e00586_bib109","doi-asserted-by":"crossref","first-page":"E4966","DOI":"10.1073\/pnas.1603244113","article-title":"Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis","volume":"113","author":"Yang","year":"2016","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.neurot.2025.e00586_bib110","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.2147\/IJN.S444115","article-title":"Current anti-amyloid-beta therapy for Alzheimer's disease treatment: from clinical research to nanomedicine","volume":"18","author":"Zhao","year":"2023","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.neurot.2025.e00586_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.124231","article-title":"Abeta-oligomers: a potential therapeutic target for Alzheimer's disease","volume":"239","author":"Ghosh","year":"2023","journal-title":"Int J Biol Macromol"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00586_bib112","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1007\/s12035-020-01988-1","article-title":"The Sigma-2 receptor\/TMEM97, PGRMC1, and LDL receptor complex are responsible for the cellular uptake of Abeta42 and its protein aggregates","volume":"57","author":"Riad","year":"2020","journal-title":"Mol Neurobiol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00586_bib113","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12929-023-00976-6","article-title":"Clinical trials of new drugs for Alzheimer disease: a 2020-2023 update","volume":"30","author":"Huang","year":"2023","journal-title":"J\u00a0Biomed Sci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00586_bib114","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer's disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00586_bib115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043754","article-title":"Alzheimer's disease: an updated overview of its genetics","volume":"24","author":"Andrade-Guerrero","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00586_bib116","doi-asserted-by":"crossref","DOI":"10.1002\/bies.202300176","article-title":"Emerging small molecule inhibitors of Bach1 as therapeutic agents: rationale, recent advances, and future perspectives","volume":"46","author":"Hushpulian","year":"2024","journal-title":"Bioessays"},{"key":"10.1016\/j.neurot.2025.e00586_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101194","article-title":"Limitations to adaptive homeostasis in an hyperoxia-induced model of accelerated ageing","volume":"24","author":"Pomatto","year":"2019","journal-title":"Redox Biol"},{"key":"10.1016\/j.neurot.2025.e00586_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2020.108749","article-title":"Age-related alteration in HNE elimination enzymes","volume":"699","author":"Zhang","year":"2021","journal-title":"Arch Biochem Biophys"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:09:54Z","timestamp":1762560594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925000649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":118,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1878747925000649"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00586","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nrf2\/Bach1 signaling axis: A promising multifaceted therapeutic strategy for Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00586","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00586"}}